Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Multimodal AI Approach May Help Identify Key Elements to Predict Outcomes in RCC

July 11th 2024

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Nivolumab Plus Ipilimumab Yields Long-Term Efficacy Advantage in Advanced RCC

July 11th 2024

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.

ADI-270 Earns FDA Fast Track Designation for Pretreated Advanced ccRCC

July 8th 2024

The FDA has granted fast track designation to ADI-270 for advanced clear cell renal cell carcinoma after an immune checkpoint inhibitor and VEGF inhibitor.

Dr Subbiah on the Combination of Sapanisertib and Ziv-Aflibercept in Solid Tumors

July 3rd 2024

Vivek Subbiah, MD, discusses the rationale for combining sapanisertib with ziv-aflibercept in recurrent metastatic solid tumors, including kidney cancer.

Early Data With DFF332, Other Key Biomarker Analyses Continue to Inform Approaches in RCC

July 3rd 2024

Sumanta Kumar Pal, MD, FASCO, highlights key renal cell carcinoma research presented at the 2024 ASCO Annual Meeting, including early data with DFF332.

Dual mTORC1/mTORC2 Inhibitor Sapanisertib Shows Promise in Combination Regimens for Solid Tumors

July 2nd 2024

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

Dr Bilusic on the Investigation of Enfortumab Vedotin in Rare GU Cancers

June 26th 2024

Marijo Bilusic, MD, PhD, discusses the investigation of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors.

Dr Linscott on Urinary Cell-free Tumor DNA to Predict MRD in High-risk NMIBC

June 25th 2024

Joshua Linscott, MD, discusses using urinary cell-free tumor DNA to predict minimal residual disease in high-risk non-muscle invasive bladder cancer.

EMA Validates Filings for Subcutaneous Formulation of Nivolumab in Solid Tumors

June 21st 2024

The EMA has validated an extension application for the subcutaneous formulation of nivolumab in adult patients with solid tumor indications.

Dr Grivas on Key Updates in Genitourinary Cancer Management

June 17th 2024

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.

Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC

June 11th 2024

Benjamin L. Maughan, MD, PharmD, highlights ongoing research regarding the role of cytoreductive nephrectomy and targeted therapies in RCC.

Dr Garje on the Prognostic Value of HPV Status for Survival Outcomes in pSCC

June 10th 2024

Rohan Garje, MD, discusses the impact of human papillomavirus status on survival outcomes in penile squamous cell carcinoma.

Dr Ahluwalia on the Incidence of Brain Metastases in RCC

June 10th 2024

Manmeet Ahluwalia, MD, MBA, FASCO, discusses findings from a National Cancer Database analysis on treatment outcomes of brain metastases from primary RCC.

Braun Spotlights Novel Treatment Developments in RCC

June 10th 2024

David A. Braun, MD, PhD, highlights the developing role of T-cell therapies in RCC and looks toward the horizon for other advances.

Notable RCC Data Presented at ASCO May Shed Light on Key Biomarkers and Combination Approaches

June 7th 2024

Benjamin L. Maughan, MD, PharmD, dives into key studies in RCC regarding biomarkers and first-line treatments presented at the 2024 ASCO Annual Meeting

Braun Highlights Advances in RCC Treatment Paradigm, Looks Towards Future

June 7th 2024

David A. Braun, MD, PhD, discusses the evolving treatment landscape of renal cell carcinoma.

Advancements With Combination Therapies in RCC Usher in New Questions

June 6th 2024

Benjamin L. Maughan, MD, PharmD, discusses the implications of immuno-oncology and TKI agent combinations in clear cell and non–clear cell RCC.

Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC

June 5th 2024

Higher T-cell inflamed GEP values were positively associated with clinical outcomes for pembrolizumab plus axitinib in advanced clear cell RCC.

Lenvatinib Plus Pembrolizumab Delays Tumor Progression in All Organs vs Sunitinib in Advanced RCC

June 5th 2024

Lenvatinib/pembrolizumab offered a significant benefit in terms of time to disease progression in all organs vs sunitinib in advanced RCC.

Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC

June 3rd 2024

Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.